Royalty Pharma plc (RPRX)
Nasdaq: RPRX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2020
Grade6.3
◀ Past 6.5● Present 7.2▶ Future 5.0
Who owns Royalty Pharma plc
As filed with the SECHolders of 5% or more
5
Legorreta G. Pablo holds 18.7% of Class A ordinary shares, par value $0.0001 per share, as its SCHEDULE 13D/A filed Aug 17, 2026 says.
Directors and officers
14
report now, of 22 people on the record since 2002. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Legorreta G. Pablo
SCHEDULE 13D/A · filed Aug 17, 2026 · Class A ordinary shares, par value $0.0001 per share · 19.7% in May 23, 2025
Morgan Stanley
SCHEDULE 13G/A · filed Aug 5, 2025 · Class A Ordinary Shares
Capital International Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock · 7.7% in Feb 13, 2026
Fmr LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · CLASS A COMMON STOCK · 9.1% in May 12, 2025
Blackrock, Inc.
Butterfield Fiduciary Administrators Trust Company Limited
SCHEDULE 13D/A · filed Jun 16, 2026 · Class A Ordinary Shares, par value $0.0001 per share · reported falling below 5%, from 5.7% in Feb 20, 2026
General Atlantic, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Class A ordinary shares, par value US$0.0001 per share · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Oct 30, 2025 · Common Stock · reported falling below 5%
What RPRX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Continuing Investors Partnership
An entity · legal entity · owns, named in the 10-K filed Feb 11, 2026
Founder's Equity
An entity · legal entity · owns, named in the 10-K filed Feb 11, 2026
Royalty Pharma Select Finance Trust
An entity · legal entity · owns, named in the 10-K filed Feb 11, 2026
RP Holdings Class E Interests Holders
An entity · legal entity · owns, named in the 10-K filed Feb 11, 2026
Avillion I
An investee · investee · invested in, named in the 10-K filed Feb 11, 2026
Avillion II
An investee · investee · invested in, named in the 10-K filed Feb 11, 2026
RP Manager
A company bought · acquisition · May 2025 · owns, named in the 10-K filed Feb 11, 2026
8 subsidiaries in 3 countries, from the list filed with the 10-K filed Feb 11, 2026.
Insider tradesForm 4
74sales
0purchases
74sales on a scheduled plan
5people selling
$92.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO | 35 | $39.0M | 35 | 0 | $0 |
| Hite Christopher | EVP & Chairman, Partnering | 9 | $27.4M | 9 | 0 | $0 |
| Lloyd George W. | EVP, Investments & CLO | 11 | $13.8M | 11 | 0 | $0 |
| Urist Marshall | EVP, Research & Investments | 18 | $12.5M | 18 | 0 | $0 |
| Norden Gregory | director | 1 | $200,000 | 1 | 0 | $0 |